Patents Assigned to Janssen Pharmaceuticals, Inc.
  • Patent number: 11555205
    Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: January 17, 2023
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Martina Felderman, Nancy C. Carrico
  • Publication number: 20220409583
    Abstract: The present invention relates to the use of substituted indole derivatives and substituted indoline derivatives in the manufacture of a medicament for the treatment of dengue disease in an individual infected by dengue virus or the prevention of dengue disease in an individual at risk of being infected by Dengue virus. The invention further provides a method for the treatment or the prevention of dengue in an individual at risk of being infected by Dengue virus.
    Type: Application
    Filed: November 13, 2020
    Publication date: December 29, 2022
    Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Olivia Gabriella M. GOETHALS, Bart Rudolf Romanie KESTELEYN, Bart Henri Theresia STOOPS, Jean-François BONFANTI, Tim Hugo Maria JONCKERS, Marnix VAN LOOCK, Suzanne KAPTEIN, Johan NEYTS
  • Patent number: 11529405
    Abstract: The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: December 20, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Eszter Nagy, Gäbor Nagy, Valéria Szijárto, Zóltan Magyarics, Irina Mirkina, Luis Gauchalla, Adriana Badarau, Gerhild Zauner, Jolanta Lukasiewicz
  • Patent number: 11498944
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: January 30, 2021
    Date of Patent: November 15, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel Le Gars, Jerald C. Sadoff
  • Patent number: 11491220
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 8, 2022
    Assignees: Janssen Pharmaceuticals, Inc.
    Inventors: Jeroen Geurtsen, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Jan Theunis Poolman, Kellen Cristhina Fae, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Patent number: 11484582
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: November 1, 2022
    Assignees: Janssen Pharmaceuticals, Inc.
    Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
  • Publication number: 20220340522
    Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Application
    Filed: June 16, 2022
    Publication date: October 27, 2022
    Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Jérôme Michel Claude Fortin, Guillaume Jean Maurice Mercey, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 11446370
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: September 20, 2022
    Assignees: Janssen Pharmaceuticals, Inc., GlaxoSmithKline Biologicals S.A.
    Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Patent number: 11446446
    Abstract: An accessory for an injection device having a needle cap. The accessory comprises a body portion comprising a recess adapted to receive the injection device and a cover coupled to the body portion. The cover is pivotally moveable between an open position in which the recess is exposed to receive the injection device, and a closed position in which the cover at least partially closes the recess to hold the injection device in the body portion. The accessory further comprises a cap remover comprising a grip, the cap remover having an expanded configuration in which the needle cap can pass between the grip, and a constricted configuration in which the grip holds the needle cap to at least partially remove the needle cap from the injection device.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: September 20, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James D. McLusky, Nick Foley, Gavin F. McDougall, Roy A. Crerar, James N. Mower
  • Patent number: 11421003
    Abstract: Polypeptides comprising a FimH lectin domain comprising an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 23, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Jan Grijpstra, Marleen Eveline Weerdenburg, Jeroen Geurtsen, Cristhina Kellen Fae, Jakob Louris Feitsma
  • Patent number: 11407715
    Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: August 9, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Jérôme Michel Claude Fortin, Guillaume Jean Maurice Mercey, Pierre Jean-Marie Bernard Raboisson
  • Publication number: 20220227819
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 21, 2022
    Applicants: The University of Chicago, Janssen Pharmaceuticals, Inc.
    Inventors: Dominique Missiakas, Olaf Schneewind, Carla Emolo, Lena Thomer, Molly McAdow, Jeroen Geurtsen, Mark De Been
  • Patent number: 11384122
    Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: July 12, 2022
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel le Gars, Jerald C. Sadoff
  • Publication number: 20220193085
    Abstract: Methods of thromboprophylaxis using rivaroxaban is provided for children with congenital heart disease post-Fontan procedure.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 23, 2022
    Applicants: JANSSEN PHARMACEUTICALS, INC., BAYER PHARMA ATKIENGESELLSCHAFT
    Inventors: CHRISTOPHER NESSEL, Stefan Willmann, Dagmar Kubitza, Roger M. Mills, Catherine Vanden Boom, Elliot Barnathan, Liza Miriam Pina
  • Patent number: 11364310
    Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecules of interest. The disclosure relates to nucleic acid constructs, such as expression vectors, containing a modified replicon RNA which includes a modified 5?-unstranslated region (5?-UTR) and, optionally, at least some of its original viral sequence encoding structural proteins having been deleted. Also disclosed are methods for producing polypeptides of interest.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: June 21, 2022
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventor: Kurt Iver Kamrud
  • Patent number: 11266627
    Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 8, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
  • Patent number: D946141
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: March 15, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Peter Krulevitch, Michael Cannamela, Yuji Ikeda, Nick Foley, James McLusky, Jimmy Mower, Scott Martin, James Glencross
  • Patent number: D946750
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: March 22, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James McLusky, Nick Foley, Jimmy Mower, Michael Cannamela, Peter Krulevitch, James Flint
  • Patent number: D956215
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: June 28, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Peter Krulevitch, Michael Cannamela, Yuji Ikeda, Nick Foley, James McLusky, Jimmy Mower, Scott Martin, James Glencross
  • Patent number: D958330
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: July 19, 2022
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James McLusky, Nick Foley, Gavin Fraser McDougall, Roy Andrew Crerar, Jimmy Mower